Piper Sandler Initiates Coverage On Roivant Sciences with Overweight Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Allison Bratzel has initiated coverage on Roivant Sciences (NASDAQ:ROIV) with an Overweight rating and set a price target of $20.
January 05, 2024 | 3:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences received an Overweight rating from Piper Sandler with a price target of $20, indicating a positive outlook from the analyst.
The initiation of coverage by Piper Sandler with an Overweight rating typically suggests a positive forecast for Roivant Sciences' stock performance. The announcement of a $20 price target further implies a significant upside potential from the current trading price, which may positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100